Everything below concerns lipogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
In February 2023, the company debuted in Australia with a store in Sydney, followed by additional openings in Melbourne and Brisbane. By the first nine months of 2023, Mixue had sold approximately 442 million ice cream cones in China. On March 3, 2025, Mixue Group went public through an initial public offering on the Hong Kong Stock Exchange in what was then the city's largest initial public offering of the year. The company sold 17 million shares at HK$202.5 each, raising about HK$3.45 billion (US$444 million). In September 2025, Mixue began plans to open a store in the United States in New York City. On December 20, 2025, Mixue opened their first American store in Hollywood, Los Angeles, and two stores opened four days later in New York City, in Herald Square and the Hell's Kitchen neighborhood. Reviewers prominently noted the chain's low prices and that items were constantly sold out.
Dyson replied that "[m]y objections to the global warming propaganda are not so much over the technical facts, about which I do not know much, but it's rather against the way those people behave and the kind of intolerance to criticism that a lot of them have." Dyson stated in an interview that the argument with Hansen was exaggerated by The New York Times, stating that he and Hansen are "friends, but we don't agree on everything." Since originally taking an interest in climate studies in the 1970s, Dyson suggested that carbon dioxide levels in the atmosphere could be controlled by planting fast-growing trees. He calculated that it would take a trillion trees to remove all carbon from the atmosphere. In a 2014 interview he said, "What I'm convinced of is that we don't understand climate... It will take a lot of very hard work before that question is settled." Dyson was a member of the academic advisory council of the Global Warming Policy Foundation.
=== Pharmacogenetics === The dihydropyrimidine dehydrogenase (DPD) enzyme is responsible for the detoxifying metabolism of fluoropyrimidines, a class of drugs that includes 5-fluorouracil, capecitabine, and tegafur. Genetic variations within the DPD gene (DPYD) can lead to reduced or absent DPD activity, and individuals who are heterozygous or homozygous for these variations may have partial or complete DPD deficiency; an estimated 0.2% of individuals have complete DPD deficiency. Those with partial or complete DPD deficiency have a significantly increased risk of severe or even fatal drug toxicities when treated with fluoropyrimidines; examples of toxicities include myelosuppression, neurotoxicity and hand-foot syndrome.
Sources: en.wikipedia.org
A group of Liberal MPs led by Sir John Simon opposed the Liberal Party's support for the minority Labour government. They preferred to reach an accommodation with the Conservatives. In 1931 MacDonald's Labour government fell apart in response to the Great Depression. Macdonald agreed to lead a National Government of all parties, which passed a budget to deal with the financial crisis. When few Labour MPs backed the National government, it became clear that the Conservatives had the clear majority of government supporters. They then forced MacDonald to call a general election. Lloyd George called for the party to leave the National Government but only a few MPs and candidates followed. The majority, led by Sir Herbert Samuel, decided to contest the elections as part of the government. The bulk of Liberal MPs supported the government – the Liberal Nationals (officially the "National Liberals" after 1947) led by Simon, also known as "Simonites", and the "Samuelites" or "official Liberals", led by Samuel who remained as the official party. Both groups secured about 34 MPs but proceeded to diverge even further after the election, with the Liberal Nationals remaining supporters of the government throughout its life. There were to be a succession of discussions about them rejoining the Liberals, but these usually foundered on the issues of free trade and continued support for the National Government. The one significant reunification came in 1946 when the Liberal and Liberal National party organisations in London merged.
International Campaign for Justice in Bhopal (ICJB), coordinates international activities Bhopal Medical Appeal, collects funds for the Sambhavna Trust Sambhavna Trust or Bhopal People's Health and Documentation Clinic. Provides medical care for gas affected patients and those living in water-contaminated area Chingari Trust, provides medical care for children being born in Bhopal with malformations and brain damages Students for Bhopal, based in the United States International Medical Commission on Bhopal, provided medical information 1994–2000 Bhopal Gas Peedit Mahila-Stationery Karmachari Sangh Bhopal Gas Peedit Mahila Udyog Sangthan
=== The aspartate family of amino acids === The aspartate family of amino acids includes: threonine, lysine, methionine, isoleucine, and aspartate. Lysine and isoleucine are considered part of the aspartate family even though part of their carbon skeleton is derived from pyruvate. In the case of methionine, the methyl carbon is derived from serine and the sulfur group, but in most organisms, it is derived from cysteine.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.